The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
- Sponsor
- Neurology Office of South Florida
- Study ID
- NCT07212062
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- X/T + X-EC — DRUGXanomeline and Trospium Chloride Capsules
- Placebo — DRUGPlacebo
- Lecanemab 10 mg/kg — DRUGParticipants will continue their current Lecanemab infusions while in the study receiving the study drug or placebo.
Study Details
The goal of the trial is to see if the Safety and Tolerability of X/T+X/T-EC combined with currently treated Lecanemab participants with Alzheimer's Disease compared with placebo. This is a 32 week study (4 weeks of screening,24 weeks of treatment and 4 weeks of safety follow up)
Key Dates
- Start date
- Dec 1, 2025
- Status verified
- Sep 2025
- Primary completion
- Apr 1, 2028
- Completion
- Dec 30, 2028
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Arm A- Lecanemab + X/T + X-ECParticipants will receive the active drug as well as their current Lecanemab treatment.
- Placebo Comparator: Arm B- Lecanemab + PlaceboParticipants will receive the non-active drug/placebo as well as their current Lecanemab treatment.
Primary Outcome Measure
Assess the safety and tolerability of X/T+X-EC compared with placebo in participants with Alzheimer's Disease currently treated with Lecanemab [ Time Frame: Baseline to week 28 as there is a 4 week follow up period after End of Treatment ]
Central Contacts
- Brian Costell, MD561-487-1027
- Tom Voulgaris, Research Director561-487-1027
Related Studies
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPHASE2/PHASE3 · Recruiting · Washington University School of Medicine · Birmingham, Alabama
- Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers DiseaseRecruiting · Emory University · Atlanta, Georgia
- Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's DiseasePHASE2 · Recruiting · Brigham and Women's Hospital · Boston, Massachusetts
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPHASE2/PHASE3 · Recruiting · Washington University School of Medicine · Birmingham, Alabama